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Abstract: The p38ʱ mitogen-activated protein kinase (MAPK) has become an attractive 
target for the treatment of many diseases such as rheumatoid arthritis, inflammatory bowel 
disease and Crohn’s disease. In this paper, 3D-QSAR and molecular docking studies were 
performed on 59 p38ʱ MAPK inhibitors. Comparative molecular field analysis (CoMFA) 
and comparative molecular similarity indices analysis (CoMSIA) were applied to determine 
the structural requirements for potency in inhibiting p38ʱ MAPK. The resulting model of 
CoMFA and CoMSIA exhibited good r
2
cv values of 0.725 and 0.609, and r
2 values of 0.961 
and 0.905, respectively. Molecular docking was used to explore the binding mode between 
the inhibitors and p38ʱ MAPK. We have accordingly designed a series of novel p38ʱ 
MAPK inhibitors by utilizing the structure-activity relationship (SAR) results revealed in the 
present study, which were predicted with excellent potencies in the developed models. The 
results provided a useful guide to design new compounds for p38ʱ MAPK inhibitors. 
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1. Introduction 
The p38 mitogen-activated protein kinase (MAPK), a serine/threonine kinase, plays a crucial role in 
biosynthesis  of  pro-inflammatory  cytokines  including  tumor  necrosis  factor  ʱ  (TNFʱ)  and 
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interleukin-1 β (IL-1β) [1]. The p38 MAPK exists in four isoforms (ʱ, β, γ and ʴ). Expression of these 
isoforms varies across cell types of the immune system, and it was revealed by previous studies that 
the predominant isoform involved in inflammation is p38ʱ [2,3]. The p38ʱ MAPK is activated by a 
range  of  environmental  stimuli  such  as  TNFʱ,  IL-1β  and  stress.  Activation  of  p38ʱ  leads  to  the 
up-regulation  of both  TNFʱ and  IL-1β,  resulting  in  many  chronic inflammatory diseases,  such as 
rheumatoid  arthritis  (RA),  inflammatory  bowel  disease,  Crohn’s  disease,  and  chronic  obstructive 
pulmonary disease (COPD), as well as the other inflammatory disorders [4–8]. 
The proven ability of p38 MAPK to efficiently regulate both the release and the activity of these 
pro-inflammatory cytokines has prompted many pharmaceutical groups to pursue inhibitors of p38 
MAPK for the potential treatment of various inflammatory diseases [9–11]. A series of fused pyrazole 
derivatives with potent, selective and orally available inhibition activities towards p38 MAPK were 
reported  [1–3].  In  this  paper,  3D-QSAR  and  molecular  docking  studies  were  performed  on  these 
inhibitors. Along with the molecular docking, 3D-QSAR approaches including comparative molecular 
field analysis (CoMFA) and comparative molecular similarity analysis (CoMSIA) could offer more 
insight into understanding the structure-activity relationship of these inhibitors, and thus could more 
effectively direct the design of new potential inhibitors. Based on the structure-activity relationship 
revealed in the present study, a series of novel p38ʱ MAPK inhibitors were accordingly designed.   
2. Materials and Methods 
2.1. Dataset for Analysis 
All the compounds and associated biological activities were selected from literature [1–3] reported 
by the same research  group. These  fused pyrazole derivatives  were divided into a training set  of 
46 compounds and a test set of 13 compounds. The inhibitory data was reported as IC50 towards p38ʱ 
MAPK, and the IC50 values were converted into corresponding pIC50 by taking Log (1/IC50). The pIC50 
values were used as the dependent variables in all the models subsequently developed. Structures and 
associated inhibitory activities are shown in Tables 1 and 2. 
Table 1. The chemical structures of the fused pyrazole derivatives used for the training and 
test set. 
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1–12                                                            13 
Compound 
No. 
Substituent 
R1  R2  R3  R4  R5 
1  Me  2-Me-Ph  Me  H  Cyclopropyl 
2  Me  2-Cl-Ph  Me  H  Cyclopropyl 
3  Me  N
CF3
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Table 1. Cont. 
Compound 
No. 
Substituent 
R1  R2  R3  R4  R5 
4  Me  2,4-Di-F-Ph  Me  H  Cyclopropyl 
5  Me  2,5-Di-F-Ph  Me  H  Cyclopropyl 
6  Me  2,6-Di-F-Ph  Me  H  Cyclopropyl 
7  Et  2,4-Di-F-Ph  Me  H  Cyclopropyl 
8  Me  2,6-Di-F-Ph  Cl  H  Cyclopropyl 
9  Me  2,6-Di-F-Ph  Me  F  Cyclopropyl 
10  Me  2,6-Di-F-Ph  Me  H  H 
11  Me  2,6-Di-F-Ph  Me  H 
 
12  Me  2,6-Di-F-Ph  Me  H 
N
O
 
13  Me  2,6-Di-F-Ph  Me  H  Methylamino 
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14–17 
Compound 
No. 
Substituent 
R1  R2  R3 
14  Me  3-F-Ph  O
 
15  Me  2,6-Di-F-Ph  F
 
16  Me  2,4-Di-F-Ph 
F
F
 
17  Me  2,5-Di-F-Ph  N
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18–39 
Compound 
No. 
Substituent 
R1  R2  X  R3  R5 
18  Me  2,4-Di-F-Ph  NH  Me  NH2 
19  Me  2,5-Di-F-Ph  NH  Me  NH2 
20  Me  2,4-Di-F-Ph  NH  Me  NHOMe Int. J. Mol. Sci. 2010, 11                         
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Table 1. Cont. 
Compound 
No. 
Substituent 
R1  R2  X  R3  R5 
21  Me    2,4-Di-F-Ph  NH    Me  Cyclopropylamino   
22  Me  2,4-Di-F-Ph  NH  Me  t-butylamino 
23  Me  2,4-Di-F-Ph  NH  Me  OH 
24  Me  3-F-Ph  NH  Me  Cyclopropylamino 
25  Me  3-F-Ph  O  Me  Cyclopropylamino 
26  Me  4-F-Ph  NH  Cl  Cyclopropylamino 
27  Et  4-F-Ph  NH  Me  Cyclopropylamino 
28  Et  4-F-Ph  NH  Cl  Cyclopropylamino 
29  Et  4-F-Ph  O  Me  Cyclopropylamino 
30  Et  2,4-Di-F-Ph  NH  Cl  Cyclopropylamino 
31  Me  2,4-Di-F-Ph  O  Me  Cyclopropylamino 
32  Me  2,5-Di-F-Ph  NH  Me  Cyclopropylamino 
33  Me  2,5-Di-F-Ph  NH  Cl  Cyclopropylamino 
34  Me  2,5-Di-F-Ph  O  Me  Cyclopropylamino 
35  Me  2,5-Di-F-Ph  O  Cl  Cyclopropylamino 
36  Me  2,6-Di-F-Ph  NH  Me  Cyclopropylamino 
37  Me  2,6-Di-F-Ph  NH  Cl  Cyclopropylamino 
38  Me  2,6-Di-F-Ph  NH  F  Cyclopropylamino 
39  Me  2,6-Di-F-Ph  O  Me  Cyclopropylamino 
N
N
N
N
X
R2 R1
R3 H
N
O
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40–59 
Compound 
No. 
Substituent 
R1  R2  X  R3  R4 
40  H  2-Cl-Ph  NH  Cl  H 
41  H  3-F-Ph  NH  Me  H 
42  H  3-F-Ph  NH  Cl  H 
43  H  4-F-Ph  NH  Cl  H 
44  H  2,4-Di-F-Ph  NH  Me  H 
45  H  2,4-Di-F-Ph  NH  Cl  H 
46  H  2,4-Di-F-Ph  O  Me  H 
47  H  2,4-Di-F-Ph  O  Cl  H 
48  H  2,5-Di-F-Ph  NH  Cl  H 
49  H  2,6-Di-F-Ph  NH  Me  H 
50  H  2,6-Di-F-Ph  NH  Cl  H 
51  H  2,6-Di-F-Ph  O  Me  H 
52  Me  4-F-Ph  NH  Me  H 
53  Me  4-F-Ph  NH  Cl  H Int. J. Mol. Sci. 2010, 11                         
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Table 1. Cont. 
Compound 
No. 
Substituent 
R1  R2  X  R3  R4 
54  Me  4-F-Ph  O  Me  H 
55  Me  2,4-Di-F-Ph  NH  Me  H 
56  Me  2,4-Di-F-Ph  NH  Me  F 
57  Me  2,4-Di-F-Ph  NH  Cl  H 
58  Me  2,4-Di-F-Ph  O  Me  H 
59  Me  2,6-Di-F-Ph  NH  Cl  H 
Table 2. The experimental pIC50 values, predicted pIC50 values (Pred.) and their residuals 
(Res.) of the pyrazole derivative training and test set molecules. 
Compd. 
No. 
Experimental 
CoMFA  CoMSIA 
Pred.  Res.  Pred.  Res. 
1  8.721  8.777  -0.056  8.957  -0.236 
2*  9.046  8.778  0.268  8.905  0.141 
3  8.638  8.682  -0.044  8.764  -0.126 
4*  8.638  8.572  0.066  8.858  -0.220 
5  8.721  8.639  0.082  8.790  -0.069 
6  8.854  8.995  -0.141  8.879  -0.025 
7  9.222  8.929  0.293  8.920  0.302 
8  8.959  9.010  -0.051  8.841  0.118 
9  9.097  9.111  -0.014  8.972  0.125 
10*  8.824  9.006  -0.182  8.873  -0.049 
11  8.770  8.972  -0.202  8.903  -0.133 
12  9.000  8.839  0.161  8.868  0.132 
13  8.699  8.742  -0.043  8.826  -0.127 
14  6.000  6.004  -0.004  5.830  0.170 
15  6.000  6.067  -0.067  6.266  -0.266 
16*  6.000  5.862  0.138  6.340  -0.340 
17  6.353  6.362  -0.009  6.273  0.080 
18  8.585  8.533  0.052  8.637  -0.052 
19*  8.432  8.568  -0.136  8.566  -0.134 
20  8.959  9.046  -0.087  9.152  -0.193 
21  8.495  8.396  0.099  7.804  0.691 
22  6.570  6.573  -0.003  6.795  -0.225 
23  6.000  5.986  0.014  6.047  -0.047 
24  8.482  8.521  -0.040  8.435  0.047 
25  8.071  8.248  -0.177  8.566  -0.495 
26  8.824  8.695  0.129  8.728  0.096 
27*  8.398  8.617  -0.219  8.565  -0.167 
28  8.921  8.985  -0.064  8.840  0.081 
29  8.398  8.533  -0.135  8.608  -0.210 
30  8.959  9.075  -0.116  8.800  0.159 
31  8.108  8.106  0.002  8.519  -0.411 
32*  8.538  8.362  0.176  8.617  -0.079 Int. J. Mol. Sci. 2010, 11                         
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Table 2. Cont. 
Compd. 
No. 
Experimental 
CoMFA  CoMSIA 
Pred.  Res.  Pred.  Res. 
33  8.959  8.696  0.263  8.676  0.283 
34*  8.215  8.192  0.023  8.449  -0.234 
35  8.482  8.504  -0.022  8.732  -0.250 
36  8.721  8.606  0.115  8.674  0.047 
37  8.959  8.939  0.020  8.735  0.224 
38  8.721  8.996  -0.275  8.744  -0.023 
39  8.854  8.546  0.308  8.543  0.311 
40  8.796  8.622  0.174  8.529  0.267 
41*  8.337  8.287  0.050  8.220  0.117 
42*  8.301  8.519  -0.218  8.450  -0.149 
43  8.071  8.410  -0.339  8.459  -0.388 
44  7.921  8.132  -0.211  8.232  -0.311 
45  8.482  8.419  0.063  8.463  0.019 
46  8.000  7.795  0.205  7.956  0.044 
47  7.444  7.754  -0.310  7.946  -0.502 
48  8.678  8.714  -0.036  8.588  0.090 
49  8.770  8.761  0.009  8.680  0.090 
50*  8.854  8.887  -0.033  8.635  0.219 
51  8.523  8.612  -0.089  8.140  0.383 
52  8.387  8.182  0.205  8.225  0.162 
53  8.638  8.409  0.229  8.457  0.181 
54  8.114  7.849  0.265  7.968  0.146 
55*  8.569  8.513  0.056  8.649  -0.080 
56  8.000  8.387  -0.387  8.627  -0.627 
57  8.796  8.648  0.148  8.605  0.191 
58*  8.201  8.444  -0.243  8.269  -0.068 
59  8.770  8.681  0.089  8.489  0.281 
* Test set molecules. 
2.2. Molecular Modeling and Alignment 
All computational studies were performed using SYBYL 8.1 molecular modeling software from 
Tripos, Inc., US [12]. 3D structures of all compounds were constructed using the Sketch Molecule 
module. Structural energy minimization was performed using the standard Tripos molecular mechanics 
force field and Gasteiger-Hü ckel charge [13]. The fragment that was used as the common structure is 
shown in Figure 1. The compound 9 was selected as a template molecule, which was one of the most 
active derivatives in the dataset. The aligned molecules of the training set are shown in Figure 2. 
2.3. CoMFA and CoMSIA Setup 
To calculate the CoMFA and CoMSIA fields, a 3D cubic lattice with grid spacing of 1  Å and 
extending to 4 Å units beyond the aligned molecules in all directions was created automatically by 
SYBYL [12]. In the CoMFA method, a sp
3 hybridized carbon atom with a charge of 1e served as the Int. J. Mol. Sci. 2010, 11                         
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probe atom to calculate steric and electrostatic fields, in which their energy values were truncated at 
30 kcal/mol  [14].  The  CoMSIA  method,  incorporating  steric,  electrostatic,  hydrophobic,  hydrogen 
bond donor and acceptor fields, was carried out using a probe atom with radius 1.0 Å, +1.0 charge, and 
hydrophobic and hydrogen bond properties of +1. The attenuation factor was set to the default value of 
0.3 [15].   
2.4. Regression Analysis and Models Validation 
Partial Least Squares (PLS) was used to linearly correlate the CoMFA and CoMSIA fields to the 
pIC50 values. The performance of both the CoMFA and CoMSIA models  was evaluated using the 
leave-one-out (LOO) method [16]. PLS was conjunct with the cross-validation option to determine the 
optimum number of components (ONC), which were then used in deriving the final CoMFA and 
CoMSIA model without cross-validation. The ONC was the number of components resulting in the 
highest  cross-validated  correlation  coefficient  (r
2
cv).  After  obtaining  the  optimum  number  of 
components, a PLS analysis was performed with no validation and column filtering 2.0 to generate the 
highest correlation coefficient (r
2) [17–19]. 
2.5. Predictive Correlation Co-Efficient (r
2
pred) 
The predictive abilities were determined from a test set of 13 compounds that were not included in 
the training set. These molecules were aligned to the template and their pIC50 values were predicted. 
The predictive correlation coefficient (r
2
pred), based on the molecules of test set, was calculated by the 
equation shown below. 
r
2
pred = (SD – PRESS)/SD 
SD is the sum of the squared deviations between the inhibitory activities of the test set and mean 
activities of the training molecules and PRESS is the sum of squared deviations between predicted and 
actual activity values for each molecule in the test set [20–22]. 
2.6. Molecular Docking 
To investigate the protein-ligand interactions, compound 9 was docked into the ATP-binding site of 
p38ʱ MAPK. The Surflex-Dock, using an empirical scoring function and a patented search engine to 
dock ligands into a protein’s binding site, was applied to study molecular docking [12]. The crystal 
structure of p38ʱ MAPK was retrieved from the RCSB Protein Data Bank (PDB entry code: 3LHJ). 
The  p38ʱ  MAPK  structure  was  utilized  in  subsequent  docking  experiments  without  energy 
minimization. The ligands were docked into the corresponding protein’s binding site by an empirical 
scoring function and a patented search engine in Surflex-Dock [12]. All ligands and water molecules 
were removed and the polar hydrogen atoms were added. Protomol, an idealized representation of a 
ligand  that  makes  every  potential  interaction  with  the  binding  site,  was  used  to  guide  molecular 
docking. The establishment of protomol demonstrates three behaviors: (a) Automatic: Surflex-Dock 
finds the largest cavity in the receptor protein; (b) Ligand: a ligand in the same coordinate space as the 
receptor; (c) Residues: specified residues in the receptor [10]. In this paper, the automatic docking was Int. J. Mol. Sci. 2010, 11                         
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applied. To visualize the binding mode between the protein and ligand, the MOLCAD (Molecular 
Computer Aided Design) program was employed. MOLCAD calculates and displays the surfaces of 
channels and cavities, as well as the separating surface between protein subunits [12]. The MOLCAD 
program provides a variety of properties and maps onto protein surfaces. In this paper, the cavity depth, 
electrostatic and lipophilic potential surfaces were established by MOLCAD. Other parameters were 
established by default in the software. 
Figure 1. Fragment used as a common structure in the alignments. 
N
N
 
Figure 2. Alignment of the molecules used in the training set. 
 
3. Results and Discussion 
3.1. CoMFA and CoMSIA Analysis 
The statistical parameters obtained from the CoMFA model are listed in Table 3. The CoMFA model, 
using 46 and 13 derivatives in the training and test sets, respectively, gave a cross-validated correlation 
coefficient (r
2
cv) of 0.725 (>0.6) with an optimized component of 6, which suggests that the model 
should be a useful tool for predicting the IC50 values. An excellent non-cross-validated correlation 
coefficient (r
2) of 0.961 with a low standard error estimate (SEE) of 0.178, F value of 160.943 and 
predictive correlation coefficient (r
2
pred) of 0.953 was obtained. Contributions of steric and electrostatic 
fields were 0.534 and 0.466, respectively. The CoMSIA model, using steric, electrostatic, hydrophobic, 
hydrogen bond donor and hydrogen bond acceptor fields,  gave a  good cross-validated correlation 
coefficient  (r
2
cv)  of  0.609  (>0.6)  with  an  optimized  component  of  6.  A  high  non-cross-validated 
correlation coefficient (r
2) of 0.905 with a SEE of 0.279, F value of 61.672 and predictive correlation 
coefficient (r
2
pred) of 0.929 was obtained. Contributions of steric, electrostatic, hydrophobic, hydrogen 
bond donor and hydrogen bond acceptor fields were 0.159, 0.137, 0.202, 0.310 and 0.192, respectively. Int. J. Mol. Sci. 2010, 11                         
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The  experimental  and  predicted  pIC50  values  and  residual  values  for  the  training  set  and  test  set 
compounds in CoMFA and CoMSIA are given in Table 2. The relationship between experimental and 
predicted  pIC50  values  of  the  training  set  and  test  set  compounds  in  CoMFA  and  CoMSIA  are 
illustrated in Figure 3(a),(b). 
Table 3. The partial least squares (PLS) results obtained using the CoMFA and CoMSIA 
models. 
PLS Statistics  CoMFA  CoMSIA 
r
2
cv
a  0.725  0.609 
r
2b  0.961  0.905 
ONC
c  6  6 
SEE
d  0.178  0.279 
F value
e  160.943  61.672 
r
2
pred
f  0.953  0.929 
Field contribution     
Steric  0.534  0.159 
Electrostatic  0.466  0.137 
Hydrophobic  -  0.202 
H-bond Donor  -  0.310 
H-bond Acceptor  -  0.192 
a  cross-validated correlation coefficient; 
b  non-cross-validated coefficient; 
c  optimal number of components; 
d  standard error of estimate; 
e  F-test value; 
f  predictive correlation coefficient. 
Figure 3. Graph of experimental versus predicted pIC50 of the training set and the test set 
using CoMFA (a) and CoMSIA (b). 
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5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5
5.5
6.0
6.5
7.0
7.5
8.0
8.5
9.0
9.5
 Training Set
 Test Set
P
r
e
d
i
c
t
e
d
 
p
I
C
5
0
 
b
y
 
C
o
M
F
A
Experimental pIC
50
 Int. J. Mol. Sci. 2010, 11                         
 
 
3366 
Figure 3. Cont. 
(b) 
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3.2. Graphical Interpretation of CoMFA and CoMSIA 
One of the attractive features of the CoMFA and CoMSIA models is the visualization of the results 
as 3D coefficient contour maps. To visualize the information content of the derived 3D-QSAR model, 
CoMFA and CoMSIA contour maps were generated to rationalize the regions in 3D space around the 
molecules where changes in each field were predicted to increase or decrease the activity. The CoMFA 
steric  and  electrostatic  contour  maps  that  are  shown  in  Figure  4  use  compound  9  as  a  reference 
structure.  In  Figure  4(a),  the  green  contours  represent  regions  of  high  steric  tolerance  (80% 
contribution)  while  the  yellow  contours  represent  regions  of  low  steric  bulk  tolerance  (20% 
contribution). In Figure 4(b), the electrostatic field is indicated by blue (80% contribution) and red 
(20%  contribution)  contours,  which  reveal  the  regions  where  electron-donating  group  and 
electron-withdrawing group would be favorable, respectively. 
As shown in Figure 4(a), the yellow contour near R1 position indicates that bulky groups would 
decrease the potency. Comparing compound 27 with 24, their activity discrepancies can be explained 
by this yellow contour. A huge green contour around the R3 and R4 position suggested that bulkier 
groups would be favored. Most of the derivatives possessed a relatively bulkier methyl substituent at 
the  R3  position,  compounds  17–19,  which  had  minor  groups  (e.g.,  H,  F),  showed  significantly 
decreased  activities.  In  Figure  4(b),  the  blue  contour  near  the  R3  position  indicates  that 
electron-donating groups may increase the activity. This may explain why compounds 17–19, without 
an electron-donating substituent at this position, were the most inactive derivatives. A red contour near 
the R4 position demonstrated that electron-withdrawing groups would benefit the activity, compound 9 
with an electron-withdrawing substituent (-F) at R4 showed significantly increased activity. Two blue 
contours around the R5 position strongly revealed that an electron-donating group would be favorable. 
Most of the compounds in the database possessed an electron-donating cyclopropyl substituent at R5, 
compounds 17–22 and 26—without an electron-donating group at this position—showed significantly 
decreased activities. Int. J. Mol. Sci. 2010, 11                         
 
 
3367 
The CoMSIA steric, electrostatic, hydrophobic, hydrogen bond donor and acceptor field contour 
maps are shown in Figure 5 using compound  9 as a reference structure. The CoMSIA steric and 
electrostatic field contour maps were almost similar to the corresponding CoMFA contour maps. 
The hydrophobic field contour map is shown in Figure 5(c), white (20% contribution) and yellow 
(80%  contribution)  contours  highlight  areas  where  hydrophilic  and  hydrophobic  properties  were 
favored. The yellow contour around the C-6 position revealed the extreme importance of the phenyl 
group at this position; replacing it with a hydrophilic group may result in decreased activity. Two white 
contours near R4 and N-15 positions indicated that hydrophilic substituents may be favored. 
The  hydrogen  bond  donor  field  contour  map  is  illustrated  in  Figure  5(d),  the  cyan  (80% 
contribution) and purple (20% contribution) contours indicate favorable and unfavorable hydrogen 
bond donor groups. The purple contour near the C′-2 position of the phenyl group in R2 indicates that a 
hydrogen bond donor would be unfavorable. In general, compounds with a hydrogen bond acceptor 
substituent (e.g., -F) at the C′-2 position showed better activities than those without a hydrogen bond 
acceptor group. The carbonyl group in the C-14 position was surrounded by a huge purple contour, 
suggesting  it  may  serve  as  a  hydrogen  bond  acceptor  and  that  removing  it  may  result  in   
decreased potency. 
The  hydrogen  bond  acceptor  field  contour  map  is  depicted  in  Figure  5(e),  the  purple  (80% 
contribution) and red (20% contribution) contours favorable and unfavorable positions for hydrogen 
bond acceptors. The purple contour near the carbonyl group in the C-14 position revealed a hydrogen 
bond acceptor substituent at this position would benefit the activity. A red contour near N-15 position 
revealed the importance of the hydrogen bond donor -NH group. 
Figure  4.  CoMFA  Std*  coeff  contour  maps  illustrating  steric,  electrostatic  fields  in 
combination  with  compound  9.  (a)  Steric  fields:  green  contours  (80%  contribution) 
indicate  regions  where  bulky  groups  increase  activity,  while  yellow  contours  (20% 
contribution) indicate regions where bulky groups decrease activity, and (b) Electrostatic 
fields: blue contours (80% contribution) indicate regions where electron-donating groups 
increase  activity,  while  red  contours  (20%  contribution)  indicate  regions  where 
electron-withdrawing groups increase activity. 
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Figure  5.  Std*  coeff  contour  maps  of  CoMSIA  illustrating  steric,  electrostatic, 
hydrophobic, hydrogen bond donor and acceptor fields in combination with compound 9. 
(a) Steric contour map. Green contours refer to sterically favored regions while yellow 
contours refer to sterically disfavored regions. (b) Electrostatic contour map. Blue contours 
refer to regions where electron-donating groups are favored; red contours indicate regions 
where  electron-withdrawing  groups  are  favored.  (c)  Hydrophobic  contour  map.  White 
contours (80% contribution) refer to regions where hydrophilic substituents are favored; 
yellow contours (20% contribution) indicate regions where hydrophobic substituents are 
favored. (d) Hydrogen bond donor contour map. The cyan (80% contribution) and purple 
(20%  contribution)  contours  indicate  favorable  and  unfavorable  hydrogen  bond  donor 
groups. (e) Hydrogen bond acceptor contour map. The purple contours (80% contribution) 
for  hydrogen  bond  acceptor  groups  increase  activity,  red  contours  (20%  contribution) 
indicate the disfavored region. 
   
(a)                                                                      (b) 
   
(c)                                                                    (d) 
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3.3. Docking Analysis 
To explore the interaction mechanism between these inhibitors and the receptor, compound 9 was 
selected for more detailed analysis. The MOLCAD Robbin surfaces structure of the ATP pocket of the 
p38ʱ MAP within the compound 9 is shown in Figure 6. The -F at C′-2 position acted as a hydrogen 
bond acceptor and formed a H-bond with the -NH of the Met 109 residue, the carbonyl group at C-14 
position also acted as a hydrogen bond acceptor by forming a H-bond with the -NH of the ASP168. 
The observations obtained from Figure 6 are in agreement with that of CoMSIA hydrogen bond donor 
and acceptor contour maps. 
Figure 6. MOLCAD Robbin surfaces structure of selected compound 9 in complex with 
the ATP pocket of P38ʱ MAPK (PDB code: 3LHJ). Key residues and hydrogen bonds are 
labeled. The alpha helices are shown as yellow helices or cylinders, while beta sheets are 
shown as blue arrows and the loop regions as red tubes. 
 
The MOLCAD Robbin and Multi-Channel surfaces structure of the ATP-binding site of the p38ʱ 
MAP were also developed and displayed with cavity depth, electrostatic potential as well as lipophilic 
potential to explore the ligand-receptor interactions, furthermore, to examine the 3D contour maps 
obtained by CoMFA and CoMSIA.   
Figure  7(a)  depicts  the  MOLCAD  cavity  depth  potential  surface  of  the  ATP  pocket  within 
compound 9, the cavity depth color ramp ranges from blue (low depth values = outside of the pocket) 
to light red (high depth values = cavities deep inside the pocket). As shown in Figure 7(a), the phenyl 
group of R2 position was in the relative lower depth, while the other parts of the compound 9 were 
anchored deep inside the ATP pocket.   
Figure 7(b) demonstrates the MOLCAD electrostatic potential surface of the ATP-binding region, 
the color ramp for EP ranges from red (most positive) to purple (most negative). In Figure 7(b), the R3 
position  was  found  in  a  yellow  area,  which  indicated  that  electron-withdrawing  properties  were 
essential  for  potency;  the  R5  position  was  in  a  blue  area,  which  suggested  that  electron-donating 
properties were crucial for activity. The observations obtained from this electrostatic potential surface 
were satisfied according to the corresponding CoMFA and CoMSIA electrostatic contour maps. 
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Figure 7(c) shows the MOLCAD lipophilic potential surface of the ATP pocket, the color ramp for 
LP ranges from brown (highest lipophilic area of the surface) to blue (highest hydrophilic area). The 
phenyl group at C-5 position was in a brown area, which revealed the importance of hydrophobic 
properties for this position; the N-15 position was in a white area, which indicated the significance of 
hydrophilic properties for this position. These observations are in agreement with that obtained from 
the CoMSIA hydrophobic contour map. 
Figure  7.  The MOLCAD Robbin  and Multi-Channel  surfaces  structure displayed with 
cavity depth (a), electrostatic (b) and lipophilic (c) potential surfaces of the ATP pocket of 
p38ʱ MAPK within the compound 9. The cavity depth color ramp ranges from blue (low 
depth values = outside of the pocket) to light red (high depth values = cavities deep inside 
the  pocket).  The  color  ramp  for  EP  ranges  from  red  (most  positive)  to  purple  (most 
negative). The color ramp for LP ranges from brown (highest lipophilic area of the surface) 
to blue (highest hydrophilic area). 
    
(a)                                                                            (b) 
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3.4. Summary of the Structure-Activity Relationship 
The  structure-activity  relationship  revealed  by  3D-QSAR  and  molecular  docking  studies  is 
illustrated in Figure 8. In detail, the minor substituent in the R1 position would be favored; the bulky, 
electron-donating groups in R3 position would increase the activity; the bulky, electron-withdrawing, 
hydrophilic groups in R4 position would benefit the potency; the minor, electron-donating substituent 
in R5 position would be favorable; the -F at the C′-2 position and the carbonyl group at C-14 position 
are crucial for binding to the ATP pocket. 
Figure 8. Summary of structure-activity relationship revealed by 3D-QSAR and docking. 
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3.5. Design for New Inhibitors 
Based on the structure-activity relationship revealed by this study, we have designed a series of 
novel inhibitors, these molecules were aligned to the database and their activities were predicted by the 
CoMFA and CoMSIA models previously established. The chemical  structures  and predicted pIC50 
values of these compounds are shown in Table 4. The predicted pIC50 values of these compounds 
versus that of the most active compound 9 are illustrated in Figure 9. Most of the designed molecules 
showed  better  pIC50  values  than  compound  9,  which  validated  the  structure-activity  relationship 
obtained in this study. 
Figure 9. Graph of the predicted pIC50 values of the designed inhibitors using CoMFA and 
CoMSIA. 
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Table 4. Chemical structures of the newly designed inhibitors and their pIC50 values. 
N
N
N O
R1
H
N
O
R5
R3
R4
F
F
 
No. 
Substituent  Predicted pIC50 
R1  R3  R4  R5  CoMFA  CoMSIA 
D1  Me  CH2OOCCH3  COOH  Et  9.253  8.961 
D2  Me  CH2OOCCH3  CONH2  Et  8.881  9.438 
D3  Me  C(CH3)3  COOH  Et  9.093  8.343 
D4  Me  OC(CH3)3  SO3H  Et  10.845  8.064 
D5  Me  CH2OOCCH3  SO3H  Et  9.604  8.835 
D6  Me  C(CH3)3  SO3H  Et  9.171  8.970 
D7  H  C(CH3)3  COOH  Me  9.056  8.885 
D8  Me  OC(CH3)3  NO2  Et  9.210  8.667 
D9  Me  OCH(CH3)2  NO2  Et  9.168  8.638 
D10  Me  CH2OOCCH3  NO2  Et  9.792  8.668 
D11  Me  OC(CH3)3  CN  Et  9.129  9.052 
D12  Me  OCH(CH3)2  CN  Et  9.288  8.966 
D13  Me  C(CH3)3  CN  Et  9.651  9.121 
D14  H  C(CH3)3  CF3  Et  9.245  9.408 
D15  H  OC(CH3)3  CF3  Et  8.857  9.328 
D16  Me  C(CH3)3  CF3  Et  9.430  9.250 
4. Conclusion 
In conclusion, the 3D-QSAR and docking models established in our present study are quite reliable 
to efficiently guide further modification of the fused pyrazole derivatives for obtaining better inhibitors. 
Both the CoMFA and CoMSIA models provided the significant correlations of biological activities 
with steric, electrostatic, hydrophobic, hydrogen bond donor and acceptor fields. In comparison to 
CoMSIA, the CoMFA method was found to afford a slightly better predictability. The structure-activity 
relationships revealed by 3D-QSAR and docking were validated by newly designed derivatives. The 
results served as a useful guideline for developing novel p38ʱ MAPK inhibitors. 
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